Pacer Advisors
PTLA

Pacer Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Pacer Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,315
Closed -$221K – 1154
2018
Q3 		$221K Buy
+8,315
New +$271K 0.01% 1017
2018
Q1 		– Sell
-1,950
Closed -$95K – 1168
2017
Q4 		$95K Sell
1,950
-5,641
-74% -$285K 0.01% 965
2017
Q3 		$410K Buy
+7,591
New +$446K 0.04% 767

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pacer Advisors's PTLA Position: Q4 2018 in Review

Pacer Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 8,315 shares — an estimated $221K sold.

Pacer Advisors first reported a position in PTLA in Q3 2017 and held it in 3 quarters. The position peaked at $410K in Q3 2017. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

  • Pacer Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Pacer Advisors sold 8,315 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $221K.
  • Pacer Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q3 2017 and held it in 3 quarters.
  • Pacer Advisors's Portola Pharmaceuticals, Inc. position peaked at $410K in Q3 2017.
  • 181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on Pacer Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.